We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Companies in rapid pursuit of Btk immunokinase.
- Authors
Sheridan, Cormac
- Abstract
The article reports on the move by several companies to develop the Bruton's tyrosine kinase (Btk) inhibitor drugs. The drug is being developed against B-cell malignancies and with added potential in B cell-driven autoimmune disease. It cites the move by New Jersey-based Celgene to acquire Avila Therapeutics for an initial payment of 350 million dollars. The other firms pursuing the drug include California-based Pharmacyclics and Janssen Biotech, a subsidiary of Johnson & Johnson.
- Subjects
PROTEIN-tyrosine kinase inhibitors; JANSSEN Biotech Inc.; AUTOIMMUNE diseases; MERGERS &; acquisitions; CELGENE Corp.; AVILA Therapeutics Inc.
- Publication
Nature Biotechnology, 2012, Vol 30, Issue 3, p199
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0312-199